It's all in the details when it comes to Benedict's wedding look.
Renowned biotechnology researcher Zephaniah Dhlamini has been appointed Acting Pro-Vice Chancellor for Innovation and Business Development (IBD) at the National University of Science and Technology (N...
Bloodborne was just one of a number of projects Bluepoint had rejected before it was shuttered earlier this month.Bluepoint, the studio behind the successful Shadow of the Colossus and Demon's Souls remakes, reportedly pitched a Bloodborne remake last year that was rejected not by Sony, as many have thought, but by FromSoftware.This comes from a new Bloomberg report discussing the reasons Bluepoint was shut down ...
We talked to members of Apple's Vision Pro design team to find out how Environments so effectively augment reality while we work and watch content.The post How the Apple Vision Pro team allowed me to work remotely from a realistic version of Jupiter’s moon, Amalthea appeared first on Popular Science.
Nasa announces Artemis III mission no longer aims to send humans to moon The GuardianNASA Adds Mission to Artemis Lunar Program, Updates Architecture NASA (.gov)NASA announces major overhaul of Artemis moon program amid safety concerns, delays: "We've got to get back to basics" CBS NewsNasa’s Moon programme so slow that staff forget what to do The TelegraphNASA abruptly changes its roadmap to putting boots back on the moon CNN
TEKNOFEST to hold competitions in 51 main and 132 sub categories in 2026
Late-model Crosstrek and Forester hybrids may be affected
- Exl-111 is an investigational allergic Effector Cell Response Inhibitor (ECRI) targeting the IgE axis and is designed to disarm allergic effector cells at the source of activation - In primates, Exl-111 achieved rapid and near-complete (>99%) removal of receptor-bound IgE on basophils and induced a ~95% reduction in surface receptor (FcεRI) expression- Exl-111 was well-tolerated in cynomolgus monkeys, did not induce allergic effector-cell activation and showed no adverse effects or local injection site reactions at doses up to 100 mg/kg - In human-donor whole-blood basophils, Exl-111 potently dissociated receptor-bound IgE in less than 24 hours at therapeutically relevant concentrations without inducing activation- First subjects dosed in Phase 1 DISARM trial as Exl-111 becomes first ECRI candidate to enter clinic PALO ALTO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a novel class of allergy therapeutics, today announced new pre-clinical data further demonstrating the differentiated profile of its trifunctional allergic Effector Cell Response Inhibitor (ECRI) platform, reinforcing its potential to set a new standard in the control of allergic diseases. The data, which were presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, support the speed and efficacy of Exl-111, which is currently being evaluated in the Phase 1 DISARM trial.The preclinical pharmacokinetic (PK) and pharmacodynamic (PD) studies, conducted in cynomolgus monkeys following subcutaneous and intravenous administration, demonstrated rapid downregulation of the IgE signaling axis. Key results support the impact of the trifunctional mechanism of Exl-111:>99% removal of receptor-bound IgE from basophils, demonstrating active dissociation of cell-bound IgE~95% reduction in basophil FcεRI surface expression, substantially reducing effector-cell sensitivity to IgE-driven signalingPotent and sustained neutralization of free-IgE despite high average baseline IgE levels (>4500 ng/mL)Well-tolerated and induced no activation of allergic effector cellsNo adverse drug-related observations or local injection site reactions were noted at doses up to 100 mg/kg In vitro human-donor whole-blood basophil assays further showed rapid dissociation of receptor-bound IgE in less than 24 hours at therapeutically relevant concentrations, without inducing activation."Effector-cell sensitization is the final common pathway that converts IgE biology into real disease,” said Luke Pennington, Ph.D., Vice President of Discovery and Co-Founder of Excellergy. "These data show that Exl-111 can quickly dissociate receptor-bound IgE, drive near-complete FcεRI downregulation and sustain suppression of IgE binding, all without triggering effector-cell activation. Together, these findings support the potential for rapid and complete control of allergic activation and inflammation beyond what is achievable today. If translated clinically, this would move patients from months of ‘wait and see’ to earlier, more reliable control, with fewer allergic breakthrough episodes and less day-to-day uncertainty.”"The data presented by Excellergy at AAAAI represent a compelling mechanistic advance in allergy therapeutics,” said Leonard B. Bacharier, M.D., Janie Robinson and John Moore Lee Chair in Pediatrics and Professor of Pediatrics, Allergy/Immunology/Pulmonary Medicine at Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center. "By dissociating receptor bound IgE and substantially reducing surface FcεRI expression without triggering effector cell activation, Excellergy is addressing the biology that contributes to slower onset, variable efficacy, and persistent nonresponder rates with current therapies. I am encouraged to see this program has now advanced into the clinic, and the preclinical evidence provides confidence in translation to meaningful outcomes for patients.”"Dosing the first subjects in our Phase 1 DISARM trial marks a major milestone as we advance the first candidate from this new ECRI class of medicines into the clinic,” said Dr. Phil Brown, M.D., J.D., Chief Medical Officer. "This step brings us closer to a new era in allergy care, where patients can achieve earlier and more effective control, reclaiming their lives from debilitating allergic conditions.”The PK/PD data from the study were used for dose selection and trial design for Excellergy’s recently initiated Phase 1 DISARM trial for Exl-111 (NCT07356713). The first cohort of subjects in the trial was dosed in early February. This randomized, double-blind, placebo-controlled, single and multiple ascending dose trial of Exl-111 will enroll approximately 70 healthy participants who have not received prior anti-IgE therapy.About ExcellergyExcellergy is a biotechnology company developing a first-in-class portfolio of Effector Cell Response Inhibitors (ECRIs) for the treatment of severe IgE-mediated allergic diseases. By building on clinically validated IgE biology while introducing a new level of allergic disease control, Excellergy is advancing beyond traditional anti-IgE approaches to directly target the source of allergic signaling-IgE bound to the effector cell. The Company is headquartered in Palo Alto, California, and is backed by Red Tree Venture Capital,Samsara BioCapital and Decheng Capital. To learn more, please visit www.excellergy.com.Media Contact:Jenn Gordondna Communicationsjgordon@dnacommunications.comInvestor Contact:Laurence WattsNew Street Investor Relationslaurence@newstreetir.com
Rising Energy Costs and CLCPA Implementation Threaten Housing Affordability and ReliabilityRising utility costs continue to impact New York homeowners and builders amid CLCPA implementation.ALBANY, N.Y., Feb. 27, 2026 (GLOBE NEWSWIRE) -- The New York State Builders Association (NYSBA) today responded to the February 26 memorandum issued by the New York State Energy Research and Development Authority (NYSERDA) analyzing implementation of the Climate Leadership and Community Protection Act (CLCPA), warning that the law’s current structure poses serious risks to energy costs, economic competitiveness, and housing affordability.Although well-intentioned, the CLCPA as currently structured has created significant uncertainty in both the energy and housing markets. New York is already burdened with some of the highest energy costs and highest overall costs of living and doing business in the nation. NYSERDA’s own analysis underscores the magnitude of potential cost increases facing New Yorkers, including substantial annual increases in household energy costs, sharp increases in fuel prices, and dramatic utility cost impacts for commercial users, all of which will ripple throughout the economy and directly impact New York’s economy.We applaud Governor Hochul’s pragmatic leadership in pursuing an all-of-the-above approach to New York’s energy plan as she moves the state forward, addresses affordability, and preserves energy reliability.FOR MORE INFORMATION, PLEASE CONTACT:New York State Builders AssociationEmail: info@nysba.com | Phone: 518-465-2492A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/435ef624-1817-4a38-968e-e0ade26beb91
NASA's independent review of Boeing's Starliner crewed flight test reveals organizational failures, ignored engineering warnings, and insufficient oversight that stranded two astronauts aboard the ISS for nine months. The report issues over 30 recommendations as Starliner's future remains uncertain.
WhatsApp Business could potentially start charging users who want to link more than four devices to the same account in a future update.
A bug in Google Messages is causing severe battery drain and overheating on some devices. Here's a temporary fix while you wait for Google to push an update.
Redmi 10 Power Price in India: Redmi has launched its new smartphone Redmi 10 Power in India. The smartphone was launched along with Redmi 10A, on Wednesday, 20 April in India
The premium Alienware m15 R7 and m17 R5 highlight four new Ryzen-powered systems.
Apple is offering its new firmware update for the MagSafe accessory that promises to give you faster charging for the compatible iPhone models.
System apps with native call-recording functionality remain unaffected.
The OnePlus Nord 2T India launch may take place soon as the moniker has been spotted on the TDRA certification. The OnePlus Nord 2T's camera details have also been leaked. Here are the expected specifications of the device.
The iPhone 16 is likely to be the first Apple device to skip the camera notch.
Garena Free Fire Max redeem codes are 12-digit codes that are region-specific and can be used by players to gain an edge over rivals in every round of the battle royale game.
We are still not sure that no-charger policy will be limited to Narzo 50A Prime or it will be extended to other Realme budget, mid-segment and premium phones
